Lee S Schwartzberg MD

PubMed

• Correlation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HR+/HER2- early breast cancer.
  Stephanie L Graff, Sara M Tolaney, Lowell L Hart, Pedram Razavi, Wolfgang Janni
  Cancer. 2025-04-01
• Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates.
  Yeon Hee Park, Giampaolo Bianchini, Javier Cortés, Luca Licata, María Vidal
  Future Oncology. 2025-03-19
• Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer.
  Joyce O'Shaughnessy, Sara M Tolaney, Denise A Yardley, Lowell Hart, Pedram Razavi
  Breast. 2025-03-07

Abstracts/Posters

• Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United St...
  Lee S. Schwartzberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Safety of intravenous (IV) NEPA and oral NEPA for prevention of CINV in patients (pts) with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemothera... 
  2019 ASCO Annual Meeting - 6/1/2019
• Eflapegrastim, a novel and potent long-acting GCSF for reducing chemotherapy-induced neutropenia: Integrated results from two phase III trials in breast cancer patients. 
  2019 ASCO Annual Meeting - 6/1/2019
• 7th Community Oncology Conference 
  Global Academy for Medical Education (Elsevier), Las Vegas, Nevada - 3/30/2012